Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
The study is to assess the safety and efficacy of the anti-MUC1 CAR T cells and /or PD-1
knockout engineered T cells for patients with advanced non-small cell lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Guangdong Pharmaceutical University
Collaborators:
Guangzhou Anjie Biomedical Technology Co;LTD Guangzhou Anjie Biomedical Technology Co., Ltd. University of Technology, Sydney